secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2026-09-22T00:49:24+00:00
Accession:  0001193125-26-397037
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi furnishes Sep 2026 corporate presentation; deck details not in filing text
--------------------------------------------------------------------------------

- MGX issued a Sept 2026 corporate presentation positioning itself in precision gene editing for durable, curative medicines.
- Filing text ends after company tagline; specific pipeline, financials, or partnerships were not reproduced in this extract.
- Jian Irish, Ph.D., M.B.A. remains President and CEO per the 8-K signature block.
- Company is an emerging growth company; shares trade on Nasdaq under ticker MGX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/0001193125-26-397037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/mgx-20260921.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-397037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer